Although a prior cohort study did not show a statistically significant reduction in major cardiovascular events among patients with no previous history of cardiovascular disease [148], a meta-analysis of eight clinical trials evaluating the effect of GLP-1R agonists on cardiovascular outcomes reported a 14% reduction in major adverse cardiovascular events, with no significant heterogeneity across GLP-1R agonists or subgroups, including patients with or without previous cardiovascular disease [149]
That said, it's still likely to be responsible for some symptoms, if not all, so topping up your water levels can only help
Moreover, a down-regulation of p-NFB p65 was also demonstrated in those studies (18, 19)
Clients whose measurements improve during a session but partially return by the next appointment indicating fat mobilized is being reabsorbed rather than eliminated
Gupta A, Pahal S, Kumar V, Chaudhary A (2025) Role of monoclonal antibodies in Alzheimers disease: successes, failures, and future directions